ES2847424T3 - Bacterias del ácido láctico para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos - Google Patents

Bacterias del ácido láctico para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos Download PDF

Info

Publication number
ES2847424T3
ES2847424T3 ES18202594T ES18202594T ES2847424T3 ES 2847424 T3 ES2847424 T3 ES 2847424T3 ES 18202594 T ES18202594 T ES 18202594T ES 18202594 T ES18202594 T ES 18202594T ES 2847424 T3 ES2847424 T3 ES 2847424T3
Authority
ES
Spain
Prior art keywords
bone
bone loss
base pair
reuteri
lactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18202594T
Other languages
English (en)
Spanish (es)
Inventor
Robert Allen Britton
Laura Rae Mccabe
Eamonn Connolly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaia AB
Michigan State University
Original Assignee
Biogaia AB
Michigan State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia AB, Michigan State University filed Critical Biogaia AB
Application granted granted Critical
Publication of ES2847424T3 publication Critical patent/ES2847424T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES18202594T 2012-06-04 2013-06-04 Bacterias del ácido láctico para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos Active ES2847424T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261689338P 2012-06-04 2012-06-04

Publications (1)

Publication Number Publication Date
ES2847424T3 true ES2847424T3 (es) 2021-08-03

Family

ID=49712339

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18202594T Active ES2847424T3 (es) 2012-06-04 2013-06-04 Bacterias del ácido láctico para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
ES13800449T Active ES2711427T3 (es) 2012-06-04 2013-06-04 Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13800449T Active ES2711427T3 (es) 2012-06-04 2013-06-04 Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos

Country Status (16)

Country Link
US (4) US20150150917A1 (enExample)
EP (2) EP2854826B9 (enExample)
JP (1) JP6193981B2 (enExample)
KR (2) KR102191537B1 (enExample)
CN (1) CN104755091B (enExample)
AU (2) AU2013272330B2 (enExample)
CA (1) CA2875841C (enExample)
DK (2) DK3456334T3 (enExample)
ES (2) ES2847424T3 (enExample)
HR (1) HRP20190162T1 (enExample)
HU (1) HUE042643T2 (enExample)
LT (1) LT2854826T (enExample)
PL (2) PL2854826T3 (enExample)
SI (1) SI2854826T1 (enExample)
TR (1) TR201901771T4 (enExample)
WO (1) WO2013184064A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101915904B1 (ko) 2016-08-12 2018-11-06 한국식품연구원 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물
KR102120479B1 (ko) * 2018-10-30 2020-06-09 주식회사 종근당바이오 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
US12427174B2 (en) * 2019-02-05 2025-09-30 Biomedit, Inc. Probiotic compositions comprising lactobacillus reuteri strains and methods of use
KR102080498B1 (ko) * 2019-08-23 2020-02-24 정영옥 페룰산 및 유산균을 유효성분으로 포함하는 골감소증 개선 또는 예방용 식품 조성물
JP7596301B2 (ja) * 2019-12-02 2024-12-09 雪印メグミルク株式会社 骨強化剤
CN111718903A (zh) * 2020-06-24 2020-09-29 江南大学 一种筛选可预防和/或治疗骨质疏松的药物的方法
CN114711429B (zh) * 2021-06-08 2023-11-17 青岛蔚蓝生物股份有限公司 一株具有增强骨健康作用的罗伊氏乳杆菌及其应用
CN114634901B (zh) * 2022-05-18 2022-08-30 微康益生菌(苏州)股份有限公司 一种促进骨骼健康的干酪乳杆菌lc16及其培养方法与应用
KR102937770B1 (ko) * 2023-08-09 2026-03-12 국립한국교통대학교산학협력단 골다공증 억제 균주 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511502A2 (en) * 2002-06-13 2005-03-09 Alimentary Health Limited Probiotic therapies using lactobacillus reuteri
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
EP1918373B1 (en) * 2005-07-26 2014-08-20 Nestec S.A. Anti-obesity agent and anti-obesity food
WO2008028300A1 (en) * 2006-09-07 2008-03-13 Mcgill University Oral polymeric membrane feruloyl esterase producing bacteria formulation
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis

Also Published As

Publication number Publication date
KR20150028968A (ko) 2015-03-17
EP2854826A1 (en) 2015-04-08
HRP20190162T1 (hr) 2019-04-05
HUE042643T2 (hu) 2019-07-29
KR20200044134A (ko) 2020-04-28
US20180200313A1 (en) 2018-07-19
US9968643B2 (en) 2018-05-15
EP2854826B9 (en) 2019-05-08
CN104755091A (zh) 2015-07-01
ES2711427T3 (es) 2019-05-03
EP2854826B1 (en) 2018-11-14
AU2013272330B2 (en) 2017-11-02
PL2854826T3 (pl) 2019-06-28
EP2854826A4 (en) 2016-07-06
AU2013272330A1 (en) 2015-01-15
DK2854826T3 (en) 2019-03-11
AU2018200524B2 (en) 2019-07-18
SI2854826T1 (sl) 2019-03-29
US20150150917A1 (en) 2015-06-04
CA2875841C (en) 2021-02-02
JP2015526389A (ja) 2015-09-10
PL3456334T3 (pl) 2021-05-04
HK1211847A1 (en) 2016-06-03
JP6193981B2 (ja) 2017-09-06
EP3456334A1 (en) 2019-03-20
CA2875841A1 (en) 2013-12-12
AU2018200524A1 (en) 2018-02-15
US10232001B2 (en) 2019-03-19
CN104755091B (zh) 2020-07-21
US10537598B2 (en) 2020-01-21
LT2854826T (lt) 2019-02-11
ES2711427T8 (es) 2019-06-20
DK3456334T3 (da) 2021-01-25
TR201901771T4 (tr) 2019-03-21
WO2013184064A1 (en) 2013-12-12
KR102191537B1 (ko) 2020-12-16
US20170128501A1 (en) 2017-05-11
US20190142879A1 (en) 2019-05-16
EP3456334B1 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
ES2711427T3 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
CN100350919C (zh) 用于预防或治疗尿草酸盐过多的膳食或药物组合物
TWI757228B (zh) 含有槲皮素配糖體之筋萎縮抑制劑
ES2727373T3 (es) Bacteria productora de butirato y su uso
US20230131859A1 (en) Bioconversion of oleuropein
US11452308B2 (en) Method of selecting a probiotic
ES2351701T3 (es) USO DE ß-CRIPTOXANTINA.
JP6301024B2 (ja) フィーカリバクテリウム属細菌増殖剤
EP3706758B1 (en) Bioconversion of oleuropein
Liu et al. The effects of Bacillus subtilis QST713 and β-mannanase on growth performance, intestinal barrier function, and the gut microbiota in weaned piglets
ES2878674T3 (es) Cepa para el tratamiento y/o prevención de enfermedades inflamatorias crónicas
ES2656619T3 (es) Composición prebiótica de tilacoides
Shuangli et al. The mechanism of Bifidobacterium LPL-RH on increasing bone mineral density in ovariectomized osteoporosis rats.
Żerebiec et al. The digestive system microbiome and bone: environmental determinants and health implications–a narrative review